NCT00119392 · OUTCOME

Incidence and Severity of Acute Graft-versus-host Disease (GVHD) and Chronic GVHD.

Yttrium Y 90 Ibritumomab Tiuxetan, Fludarabine, Radiation Therapy, and Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma · Source last updated 2018-06-29

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: COUNT_OF_PARTICIPANTS
Unit: Participants
Interval / dispersion: Not reported
Time frame: At day +84

Groups in this outcome

Treatment (90Y Ibritumomab Tiuxetan, Hematopoietic Transplant)

See Detailed Description rituximab: Given IV cyclosporine: Given orally fludarabine phosphate: Given IV mycophenolate mofetil: Given orally yttrium Y 90 ibritumomab tiuxetan: Given IV peripheral blood stem cell transplantation: Undergo transplantation allogeneic hematopoietic stem cell transplantation: Undergo transplantation total-body irradiation: Undergo TBI

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Treatment (90Y Ibritumomab Tiuxetan, Hematopoietic Transplant)	40

Reported measurements

Acute GVHD: Grade 1-2

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Treatment (90Y Ibritumomab Tiuxetan, Hematopoietic Transplant)	27	Not reported	Not reported	Not reported	Not reported

Acute GVHD: Grade 3

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Treatment (90Y Ibritumomab Tiuxetan, Hematopoietic Transplant)	4	Not reported	Not reported	Not reported	Not reported

Chronic extensive GVHD

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Treatment (90Y Ibritumomab Tiuxetan, Hematopoietic Transplant)	5	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
value
27
title
Acute GVHD: Grade 1-2
categories
measurements
group Id
OG000
value
4
title
Acute GVHD: Grade 3
categories
measurements
group Id
OG000
value
5
title
Chronic extensive GVHD

denoms

counts
group Id
OG000
value
40
units
Participants

groups

description
See Detailed Description rituximab: Given IV cyclosporine: Given orally fludarabine phosphate: Given IV mycophenolate mofetil: Given orally yttrium Y 90 ibritumomab tiuxetan: Given IV peripheral blood stem cell transplantation: Undergo transplantation allogeneic hematopoietic stem cell transplantation: Undergo transplantation total-body irradiation: Undergo TBI
id
OG000
title
Treatment (90Y Ibritumomab Tiuxetan, Hematopoietic Transplant)

param Type

COUNT_OF_PARTICIPANTS

reporting Status

POSTED

time Frame

At day +84

title

Incidence and Severity of Acute Graft-versus-host Disease (GVHD) and Chronic GVHD.

type

SECONDARY

unit Of Measure

Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice